sofosbuvir / velpatasvir / voxilaprevi
This is a summary of the European public assessment report (EPAR) for Vosevi. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Vosevi.
For practical information about using Vosevi, patients should read the package leaflet or contact their doctor or pharmacist.
Vosevi : EPAR - Summary for the public (PDF/83.51 KB)
First published: 22/09/2017
Last updated: 22/09/2017
Vosevi : EPAR - Risk-management-plan summary (PDF/60.35 KB)
First published: 26/02/2019
Last updated: 13/11/2019
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
Hepatitis C, Chronic
|Anatomical therapeutic chemical (ATC) code||
Gilead Sciences Ireland UC
|Date of issue of marketing authorisation valid throughout the European Union||
IDA Business & Technology Park
20/05/2020 Vosevi - EMEA/H/C/004350 - IB/0039
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Antivirals for systemic use
Vosevi is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults.